The Global Human
Recombinant Insulin Market, by Product Type (Rapid-Acting Human Insulin,
Short-Acting Human Insulin, Intermediate-Acting Human Insulin, Long-Acting
Human Insulin, and Premixed Human Insulin), by Brand (Humalog, Novolog, Apidra,
Humulin R, Novolin R, Humulin N, Novolin N, Levemir, Lantus, Humalog Mix,
Novolog Mix, and Others), By Distribution Channel (Hospital Pharmacies, Retail
Pharmacies, and Online Pharmacies) was valued US$ 27.4 billion in 2018, and is
projected to exhibit a CAGR of 7.2% over the forecast period (2018 - 2026).
Key manufacturers are engaged in
launching novel human insulin portfolio and gaining regulatory approval for their
insulin product portfolio. For instance, in August 2014, Eli Lilly and Company
launched Jardiance (empagliflozin) as a treatment option for Type 2 diabetes
patients in the U.S. Jardiance is a sodium glucose co-transporter-2 (SGLT2)
inhibitor with Type 2 diabetes patients. In March 2016, Biocon Limited
collaborated with LaboratoriosPiSA S.A de CV (PiSA) to jointly develop and sell
a generic recombinant human insulin in America. Biocon expects the product to
launch by 2020 in the U.S. In February 2018, Novo Nordisk launched Fiaspa: a
fast-acting mealtime insulin in the U.S. Fiaspa received U.S. FDA approval and
indicated to improve glycemic control in adults with type 1 and type 2
diabetes. In December 2017, the U.S. Food and Drug Administration (FDA) approved
Sanofi’s Admelog. Admelog is a follow-on mealtime insulin, which helps people
living with diabetes manage blood sugar levels at mealtime.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1797
Browse 35 Market Data Tables and
42 Figures spread through 205 Pages and in-depth TOC on "Human Recombinant
Insulin Market, by Product Type (Rapid-Acting Human Insulin, Short-Acting Human
Insulin, Intermediate-Acting Human Insulin, Long-Acting Human Insulin, and
Premixed Human Insulin), by Brand (Humalog, Novolog, Apidra, Humulin R, Novolin
R, Humulin N, Novolin N, Levemir, Lantus, Humalog Mix, Novolog Mix, and
Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and
Online Pharmacies) - Global Forecast to 2026"
Efficient diabetes management and
ease of use creates need for advancements in current solutions of both insulin
and its delivery systems thereby, offering reduced patient discomfort. Glucose
Responsive Insulin (GRI) or smart insulin is a novel technology for people with
diabetes, which works by automatically reacting to blood sugar fluctuations in
body and responds to changing blood glucose levels. The lower or higher blood
sugar levels are lead to release of more or less insulin, respectively. Smart
insulin decreases the number of regular blood tests required and also minimizes
the number of daily dose of insulin injections. Researchers from the University
of North Carolina have been working on a smart insulin patch. For instance, in
2015, researchers reported that, smart insulin patch can use a micro-needles
system to automatically detect high blood glucose levels and administer insulin
appropriately. Key players in the human recombinant insulin market are
implementing inorganic growth strategies to develop and introduce smart insulin
technology in the market. For instance, in February 2016, Eli Lilly and Company
acquired Glycostasis, Inc., a startup company engaged in developing smart
insulin. Eli Lilly and Company is focused on developing Glycostasis’s ‘smart
insulin’ technology.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/human-recombinant-insulin-market-1797
Key takeaways of the Human
Recombinant Insulin Market:
The global human recombinant
insulin market is expected to expand at a CAGR of 7.2% during the forecast
period (2018 – 2026), owing to increasing technological advancement in
recombinant human insulin by various key players.
Long acting human insulin are projected
to grow with higher pace during the forecasted period in the product type
segment, owing to their higher efficiency and ability to offer consistent
insulin delivery throughout the day, lasting 24 hours.
Other brands hold major market
share in brand segment, due to the involvement of innovative and new human
recombinant insulin portfolio with increased patent expiry period such as
Toujeo, Tresiba, Basaglar, among others; in this segment, which further
expected to capture higher market share, during the forecast period.
Retail pharmacies holds largest
market share in distribution channel segment. As retail pharmacies offer direct
access to full range of diabetes products, covering all prescription and
over-the-counter products for patients with diabetes.
Some of the major players
operating in global human recombinant insulin market include Novo Nordisk A/S,
Eli Lilly and Company, Sanofi S.A., Julphar Gulf Pharmaceutical Industries,
Biocon Limited, Bioton S.A., Gan & Lee Pharmaceuticals, Ltd., Zhuhai United
Laboratories Co., Ltd., Wanbang Biopharmaceuticals Co., Ltd. and Dongbao
Enterprise Group Co., Ltd.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1797
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment